医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

LCT Starts Phase IIb Clinical Trial of NTCELL for Parkinson’s Disease

2016年03月24日 AM09:16
このエントリーをはてなブックマークに追加


 

SYDNEY & AUCKLAND, New Zealand

Living Cell Technologies has received approval from the Auckland Hospital Research Review Committee for the Phase IIb clinical trial of NTCELL® for Parkinson’s disease. The New Zealand Minister of Health authorised the application to conduct the trial on 12 November 2015, and the Northern A Health and Disability Ethics Committee gave its approval on 3 February 2016. The initiation meeting with all those involved in the clinical trial has been held and patient recruitment is under way.

The Phase IIb trial follows the successful Phase I/IIa trial, which met the primary endpoint of safety and showed clinically and statistically significant efficacy data in patients with Parkinson’s disease one year after NTCELL treatment.

The Phase IIb trial aims to confirm the most effective dose of NTCELL, define any placebo component of the response and further identify the initial target Parkinson’s disease patient sub group.

If the trial is successful the company will apply for provisional consent to treat paying patients in New Zealand and launch NTCELL as the first disease modifying treatment for Parkinson’s disease, in 2017.

For further information: www.lctglobal.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20160323006637/en/

CONTACT

At the Company:
Living Cell Technologies Limited
Ken
Taylor, +64 9 276 2690
Chief Executive
ktaylor@lctglobal.com
Mobile:
+64 21 796 000
or
Media Contact:
Botica Butler
Raudon Partners
Rachael Joel, +64 9 303 3862
rachaelj@botica.co.nz
Mobile:
+64 21 403 504

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Arbitrator Rules in Favor of Daiichi Sankyo in Dispute with Seagen
  • InnoCare Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory Marginal Zone Lymphoma in China
  • Disclosure of data on Agaricus blazei mushroom, KA21′s immunity-enhancing mechanism, immunological enhancement effect confirmed by human clinical trials, and candida and other types of fungal infection, Toei Shinyaku
  • Disclosure of data on effects of Agaricus blazei mushroom, KA21 strain for improvement of hair loss & gray hair in human clinical trials and promotion of hair growth in mice, Toei Shinyaku
  • Survey of degree of satisfaction with Agaricus blazei mushroom KA21 for promoting the health of senior dogs and cats among veterinarians and pet owners, Toei Shinyaku